8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Moderna, Inc. (MRNA)

Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).

Filed with the SEC on · Summarized by InvestorsBot

Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1). Investors should review the release for any material updates. 📰 $MRNA #8K #SEC

The 8‑K also includes the Inline XBRL cover page (Exhibit 104). Report signed by CFO James M. Mock on Feb 13, 2026. ✍️ $MRNA #SEC #Biotech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Moderna, Inc.

BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…

8-K · March 5, 2026

Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…

8-K · February 13, 2026

Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…

8-K · February 11, 2026

FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…

8-K · February 11, 2026

Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…

8-K · February 11, 2026

Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and…

8-K · January 12, 2026